Impact of streptozotocin on altering normal glucose homeostasis during insulin testing in diabetic rats compared to normoglycemic rats

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 2515-2525

  Qinna, Nidal A ^a   Badwan, Adnan A ^b  

^a UNIVERSITY OF PETRA   (Jordan)

^b JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY   (Jordan)

Author keywords

Animal model; Antidiabetic agents; Diabetes mellitus; Experimental; Protein delivery; Streptozotocin

Indexed keywords

GLUCOSE; INSULIN; RECOMBINANT HUMAN INSULIN; STREPTOZOCIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; FUNCTIONAL ASSESSMENT; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE ACTION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS INSUFFICIENCY; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; RAT; RECOMBINANT HUMAN INSULIN BLOOD LEVEL; SPRAGUE DAWLEY RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; COMPARATIVE STUDY; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMAN; KIDNEY; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 84929206624     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S79885     Document Type: Article

References (30)

1. King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877–894.
2. Lenzen S. The mechanisms of alloxan-and streptozotocin-induced diabetes. Diabetologia. 2008;51(2):216–226.
3. Tyrberg B, Andersson A, Borg LA. Species differences in susceptibility of transplanted and cultured pancreatic islets to the beta-cell toxin alloxan. Gen Comp Endocrinol. 2001;122(3):238–251.
4. Rakieten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep. 1963;29:91–98.
5. Szkudelski T. Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. Exp Biol Med (Maywood). 2012;237(5):481–490.
6. Awai M, Narasaki M, Yamanoi Y, Seno S. Induction of diabetes in animals by parenteral administration of ferric nitrilotriacetate. A model of experimental hemochromatosis. Am J Pathol. 1979;95(3):663–673.
7. Hansen WA, Christie MR, Kahn R, et al. Supravital dithizone staining in the isolation of human and rat pancreatic islets. Diabetes Res. 1989;10(2):53–57.
8. Kumar S, Singh R, Vasudeva N, Sharma S. Acute and chronic animal models for the evaluation of anti-diabetic agents. Cardiovasc Diabetol. 2012;11:9.
9. Etuk EU. Animal models for studying diabetes mellitus. Agric Biol J N Am. 2010;1(2):130–134.
10. Hayashi K, Kojima R, Ito M. Strain differences in the diabetogenic activity of streptozotocin in mice. Biol Pharm Bull. 2006;29(6):1110–1119.
11. Tjalve H, Wilander E, Johansson EB. Distribution of labelled streptozotocin in mice: uptake and retention in pancreatic islets. J Endocrinol. 1976;69(3):455–456.
12. Bonner-Weir S, Trent DF, Honey RN, Weir GC. Responses of neonatal rat islets to streptozotocin: limited B-cell regeneration and hyperglycemia. Diabetes. 1981;30(1):64–69.
13. Sakata N, Yoshimatsu G, Tsuchiya H, Egawa S, Unno M. Animal models of diabetes mellitus for islet transplantation. Exp Diabetes Res. 2012;2012:256707.
14. Elsayed A, Al-Remawi M, Qinna N, Farouk A, Al-Sou’od KA, Badwan AA. Chitosan-sodium lauryl sulfate nanoparticles as a carrier system for the in vivo delivery of oral insulin. AAPS Pharm Sci Tech. 2011;12(3):958–964.
15. Elsayed A, Remawi MA, Qinna N, Farouk A, Badwan A. Formulation and characterization of an oily-based system for oral delivery of insulin. Eur J Pharm Biopharm. 2009;73(2):269–279.
16. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50(6):537–546.
17. Deeds MC, Anderson JM, Armstrong AS, et al. Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models. Lab Anim. 2012;45(3):131–140.
18. Poretsky L. Principles of Diabetes Mellitus. Boston, MA, USA: Springer; 2010.
19. Palm F, Ortsater H, Hansell P, Liss P, Carlsson PO. Differentiating between effects of streptozotocin per se and subsequent hyperglycemia on renal function and metabolism in the streptozotocin-diabetic rat model. Diabetes Metab Res Rev. 2004;20(6):452–459.
20. Rauter AP, Martins A, Borges C, et al. Antihyperglycaemic and protective effects of flavonoids on streptozotocin-induced diabetic rats. Phytother Res. 2010;24(suppl 2):S133–S138.
21. Cañas X, Fernández-López JA, Ardévol A, et al. Rat insulin turnover in vivo. Endocrinology. 1995;136(9):3871–3876.
22. Doherty JJ 2nd, Kay DG, Lai WH, Posner BI, Bergeron JJ. Selective degradation of insulin within rat liver endosomes. J Cell Biol. 1990;110(1):35–42.
23. Toschi E, Camastra S, Sironi AM, et al. Effect of acute hyperglycemia on insulin secretion in humans. Diabetes. 2002;51(suppl 1):S130–S133.
24. Nichols CG, Remedi MS. The diabetic beta-cell: hyperstimulated vs hyperexcited. Diabetes Obes Metab. 2012;14(suppl 3):129–135.
25. Song SH, Kjems L, Ritzel R, et al. Pulsatile insulin secretion by human pancreatic islets. J Clin Endocrinol Metab. 2002;87(1):213–221.
26. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90(1):493–500.
27. Grant CW, Duclos SK, Moran-Paul CM, et al. Development of standardized insulin treatment protocols for spontaneous rodent models of type 1 diabetes. Comp Med. 2012;62(5):381–390.
28. Thibault C, Laury MC, Bailbe D, Ktorza A, Portha B. Effect of prolonged in vivo glucose infusion on insulin secretion in rats with previous glucose intolerance. Endocrinology. 1992;130(5):2521–2527.
29. Wi JK, Kim JK, Youn JH. Reduced glucose clearance as the major determinant of postabsorptive hyperglycemia in diabetic rats. Am J Physiol. 1998;274(2 pt 1):E257–E264.
30. Elsayed A. Oral delivery of insulin: novel approaches. In: Sezer A, editor. Recent Advances in Novel Drug Carrier Systems. InTech: 2012.